The Ledger

Viatris, the generic and branded drugmaker, agreed October 8 to buy Pacira BioSciences, maker of the non-opioid pain drugs Exparel and Zilretta, for $36.50 a share in cash, an equity value of about $1.65 billion. Viatris will launch a tender offer for all Pacira shares, followed by a second-step merger at the same price for any shares not tendered, and expects to close by the end of 2026. Pacira reported about $746 million in revenue and about $177 million in adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the twelve months ended June 30, 2026. Viatris says it will pay mainly from cash on hand with the rest from short-term borrowing, and that the effect on its gross leverage ratio will be minimal. Both boards approved; closing requires a majority of Pacira shares to tender and the expiration of the regulatory waiting period. Exparel is injected at the surgical site to manage post-operative pain, so the buyer now owns a product that hospitals and surgery centers buy per case as an alternative to opioid-based regimens. Watch whether pricing and contracting for those products change after close; the release does not say. Confidence: High on terms. Source: Viatris 8-K press release, Exhibit 99.1. Supplemental: BioPharma Dive.

Oracle Health’s 2025 breach of old Cerner servers reportedly reached nearly 20 million people, the first count of its size, and Oracle has not confirmed it. Bloomberg, citing a Texas attorney general report, put the total near 20 million; Cerner’s entry on the Texas attorney general’s breach portal, published October 2, lists 2,992,244 affected Texans, per SecurityWeek, which also reports roughly 283,000 South Carolina residents and 69,000 Washington residents. Oracle told customers an attacker used stolen customer credentials to reach a legacy server and copy data to a remote system after January 22, 2025; Oregon filings give the window as January 22 through April 1, 2025. Exposed data may include names, Social Security numbers, diagnoses, medicines, test results and images. For hospital operators the so-what is vendor exposure: the breach sat on infrastructure customers had not yet moved off a legacy platform, and notification duties and litigation risk fall on the health systems whose patients were affected. Confidence: Low to Medium. Per reporting; the state portal entries were not reviewed directly this run, so primary documents are not yet confirmed, and the national total comes from reporting citing an unseen filing. Source (trade press, supplemental only): SecurityWeek.

Tariffs on patented drug imports now apply to every company, not just the first group named, since September 29, and smaller drugmakers say they cannot tell how to qualify for relief. Under the April 2, 2026 Section 232 proclamation, the default rate is 100 percent on patented pharmaceuticals and their active ingredients. The rate is 20 percent for companies with Commerce-approved onshoring plans, 15 percent for goods from Japan, the European Union, South Korea and Switzerland, and 10 percent for the United Kingdom. Orphan-only drugs, nuclear medicines, plasma-derived therapies, cell and gene therapies and antibody-drug conjugates can qualify for zero in some circumstances, and companies with pricing agreements with the Department of Health and Human Services that qualify for the 20 percent rate pay zero until January 20, 2029. Generics and biosimilars are not covered “at this time,” and the Commerce secretary must report on generics within a year. Companies in Annex III began paying July 31; everyone else began September 29. The operator read: hospital pharmacy and group purchasing teams buy mostly generics, so near-term exposure sits in branded and specialty lines from manufacturers without a pricing or onshoring deal. Confidence: High on the proclamation’s terms; Medium on the cost effect, which depends on annexes not reviewed this run. Sources: White House proclamation, Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients. Supplemental: STAT, October 8.

Chicago’s Roseland Community Hospital will suspend labor and delivery by the end of October, citing the finances of safety-net hospitals, per local reporting. NBC Chicago reports an October 31 effective date; Becker’s lists it among hospitals closing departments or ending services. The hospital told state officials in July it was short on cash, asked for emergency state aid to cover payroll and vendor bills, and began an austerity plan that includes a 10 percent pay cut for senior executives and furloughs for about 30 staff members. Becker’s counts 23 maternity service closures in 2026 so far. The so-what for nearby systems and payers: births shift to other hospitals, and Medicaid managed care plans in the area will need network capacity for deliveries. Confidence: Low to Medium. The hospital’s own notice was not retrieved this run, so this rests on trade and local press. Sources: NBC Chicago, Becker’s Hospital Review, hospitals closing departments.

THE DEAL SHEET

Our scan did not surface other new healthcare transactions announced October 8 or 9, and found no new hospital bankruptcy filing or rating agency sector action dated those days.